| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 11
| Issue : 6 | Page : 212-221 |
|
|
Non-vitamin K antagonist oral anticoagulants for COVID-19 thrombosis
Adel Khalifa Sultan Hamad
Department of Electrophysiology, Mohammed bin Khalifa bin Salman Al Khalifa Cardiac Centre, Awali, Kingdom of Bahrain
Correspondence Address:
Adel Khalifa Sultan Hamad
Department of Electrophysiology, Mohammed bin Khalifa bin Salman Al Khalifa Cardiac Centre, Awali
Kingdom of Bahrain
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/2221-6189.362812
|
|
|
Thrombotic complications appear to be a major predictor of death in COVID-19 patients, and multiple studies have shown that anticoagulants can help to improve the outcome. The Food and Drug Administration’s acceptance of non-vitamin K antagonist oral anticoagulants (NOACs) has sparked much excitement about their potential as a replacement for existing oral anticoagulants. NOACs target a single clotting factor, often activated factor X or thrombin, and involve the coagulation factor Xa inhibitors including apixaban, edoxaban, and rivaroxaban, and the thrombin inhibitor dabigatran. COVID-19 is an infectious disease that causes thrombotic events by inducing a pro-inflammatory and prothrombotic condition. This article provides a comprehensive overview of the mechanism behind enhanced thrombogenicity accompanying COVID-19, the clinical range of NOACs, and the role of NOACs in treatment of COVID-19 based on recent investigations and clinical trials.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
